Anavex Life Sciences Corp (AVXL)

[JB3729]

Dr. Macfarlane expressed a view that is shared by many clinicians -

http://www.fiercebiotech.com/financials/will-eli-lilly-s-11th-hour-regulatory-gambit-salvage-or-sink-its-alzheimer-s-drug?mkt_tok=3RkMMJWWfF9wsRokuKnMd%252B%252FhmjTEU5z17%252BktUaK%252Fg4kz2EFye%252BLIHETpodcMSspjNbrYDBceEJhqyQJxPr3HJdQN18R7RhHnDg%253D%253D&mrkid=%257B%257Blead.Id%257D%257D&utm_medium=nl&utm_source=internal

Many of the clinicians in the field would far prefer to see an improvement in function, Schenk adds, with practical evidence that patients are better able to care for themselves day to day, than in cognition, where there's likely to be less agreement on the significance of an observed improvement as "different parts of the brain do different things."